 VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 GLOBE NEWSWIRE -- InMed Pharmaceuticals Inc. InMed or the Company Nasdaq: INM, a leader in the manufacturing and clinical development of rare cannabinoids, today announced that they have completed the previously announced acquisition of BayMedica Inc. BayMedica, a private company based in the US specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector. 